Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20559648 | 1.00 | PTGS1 (0.59) | PTGS1PTGS2AOC3HTTKDM1A | |
| SCHEMBL3669879 | 1.00 | PTGS1 (0.59) | PTGS1PTGS2AOC3HTTKDM1A | |
| SCHEMBL22077025 | 0.94 | PTGS1 (0.54) | PTGS1PTGS2AOC3HTTKDM1A | |
| SCHEMBL29337497 | 0.92 | PTGS1 (0.51) | PTGS1PTGS2AOC3HTTKDM1A | |
| SCHEMBL3704721 | 0.88 | TAAR1 (0.56) | PTGS1PTGS2KDM4ETAAR1SLC6A2 | |
| SCHEMBL1254034 | 0.88 | TAAR1 (0.56) | PTGS1PTGS2KDM4ETAAR1SLC6A2 | |
| SCHEMBL16325098 | 0.88 | TAAR1 (0.56) | PTGS1PTGS2KDM4ETAAR1SLC6A2 | |
| Hydrochloric Acid SCHEMBL25420079 | 0.86 | TAAR1 (0.54) | PTGS1PTGS2KDM4ETAAR1SLC6A2 | |
| Hydrochloric Acid SCHEMBL17476761 | 0.86 | TAAR1 (0.54) | PTGS1PTGS2KDM4ETAAR1SLC6A2 | |
| SCHEMBL71414 | 0.83 | PTGS1 (0.62) | PTGS1PTGS2AOC3HTTKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518166-B | Peptidomimetics compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 中国药科大学 | 2023-01-31 | — | — | CN | claimed |
| EP-3354727-B1 | TRANSAMINASE POLYPEPTIDES | CODEXIS INC (US) | 2020-10-07 | — | — | EP | claimed |
| EP-3354727-A1 | TRANSAMINASE POLYPEPTIDES | Codexis, Inc. (US) | 2018-08-01 | — | — | EP | claimed |
| EP-2385983-B1 | TRANSAMINASE POLYPEPTIDES | CODEXIS INC (US) | 2017-12-20 | — | — | EP | claimed |
| US-20100209981-A1 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-08-19 | — | — | US | claimed |
| US-20260028600-A1 | TRANSAMINASE POLYPEPTIDES | CODEXIS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12448611-B2 | Transaminase polypeptides | CODEXIS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240150732-A1 | TRANSAMINASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2024-05-09 | — | — | US | disclosed |
| US-11939602-B2 | Transaminase polypeptides | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2024-03-26 | — | — | US | disclosed |
| US-20230120624-A1 | TRANSAMINASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-04-20 | — | — | US | disclosed |
| CN-111518166-B | Peptidomimetics compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 中国药科大学 | 2023-01-31 | — | — | CN | disclosed |
| US-11542485-B2 | Transaminase polypeptides | CODEXIS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-8470564-B2 | Transaminase polypeptides | CODEXIS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| EP-2385983-A2 | TRANSAMINASE POLYPEPTIDES | Codexis, Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| US-D646886-S1 | Tip of an umbrella | Pro Performance Sports, L.L.C. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100209981-A1 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100209981-A1 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100209981-A1 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2010081053-A2 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010081053-A2 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028600-A1 | TRANSAMINASE POLYPEPTIDES | GOT1, OAT, PEPD | PTGS1 2757/4885PTGS2 2801/4885AOC3 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.